Radiotherapy (RT), which is a therapeutic treatment modality that is commonly used for cancer, employs high‐energy irradiation to induce the generation of reactive oxygen species (ROS) and to cause DNA damages. Nevertheless, the therapeutic efficacy of RT is predominantly constrained due to inadequate DNA damage in malignancies and deleterious impacts on healthy tissues. In the current study, bovine serum albumin (BSA)–coated AgBiS2 nanodots, also known as AgBiS2@ BSA nanodots, were developed for enhanced breast cancer treatment. This was accomplished by the use of an extremely simple and eco‐friendly method. Both scanning transmission electron microscopy (STEM) and scanning electron microscopy (SEM) images revealed that prepared nanoradiosensitizers, AgBiS2@ BSA, were spherical in shape and uniformly distributed. AgBiS2@ BSA nanodots possessed excellent biocompatibility and exhibit excellent monodispersity as well. Furthermore, in vitro assays such as MTT, colony formation assay, and intracellular ROS generation assay revealed the significant cell inhibitory impact of the produced AgBiS2@ BSA nanodots under X‐ray irradiation under X‐ray irradiation. Remarkably, the combined administration of AgBiS2@ BSA nanodots along with X‐ray irradiation increased ROS level within cells by increasing the localized radiation dosage and improving the anti‐tumor effectiveness of RT.

In this study, we investigated the impact of FOXN3 on esophageal cancer progression and its underlying mechanism. Through online databases, we observed a significant decrease in FOXN3 levels in esophageal cancer tissues and EC9706 cells. Conversely, SIRT1 expression was elevated in EC109 and EC9706 cells. FOXN3 was found to interact with SIRT1, AKT1, and PIK3CA. To explore FOXN3′s effects, we treated EC9706 cells with pcDNA-FOXN3, which led to increased FOXN3 levels. Consequently, SIRT1, p-AKT/AKT, p-PI3K/PI3K ratios, cell proliferation,migration, invasion, and expression of Ki67, PCNA, MMP3, MMP9, N-cadherin, Vimentin, and Bcl-2 were reduced. In contrast, cell apoptosis, E-cadherin, and Bax levels increased. Further analysis revealed that FOXN3 inhibited cell proliferation and epithelial-mesenchymal transition (EMT) while promoting apoptosis by down-regulating the SIRT1/PI3K/AKT pathway. In conclusion, FOXN3 plays a crucial role in esophageal cancer progression by modulating the SIRT1/PI3K/AKT pathway, affecting cell proliferation, EMT, and apoptosis. This study highlights FOXN3 as a potential target for therapeutic interventions in esophageal cancer.

目的:探讨放疗口腔剂量与放射性口腔黏膜炎(RTOM)的相关性,以指导临床放疗计划制定及实施.方法:选取2017年3月～2020年12月弋矶山医院放疗科62例接受放疗的头颈部肿瘤患者,获取剂量体积直方图(DVH)数据及RTOM分级并记录,采取ROC曲线计算最佳剂量截点,分析放疗口腔剂量与RTOM的相关性.结果:ROC曲线显示,平均剂量(Dmean)预测RTOM分级的AUC为0.884(0.777～0.992),其诊断最佳截点为3241.25 cGy,灵敏度为100.00％,特异度为75.40％;分为低剂量组(<3241.25 cGy)和高剂量组(≥3241.25 cGy).Dmean低剂量组治疗患者R值高于高剂量组治疗患者(P<0.05);Dmean低剂量组治疗患者RTOM分级低于高剂量组治疗患者(P<0.05);而Dmean低剂量组与高剂量组治疗患者在治疗过程中累计化疗次数差异无统计学意义(P>0.05).结论:口腔黏膜Dmean及R值与RTOM有直接相关性,通过限制口腔黏膜Dmean在32 Gy以下及提高R值,可以降低重度RTOM的发生.

In this study, a green protocol for supporting CuO nanoparticles over chitosan-modified amino-magnetic nanoparticles is described. The physicochemical and morphological properties of the desired nanocomposite assessed by various techniques like ICP, FT-IR, FE-SEM, EDX, TEM, XRD and VSM. In the oncological part of the recent study, the Cu(NO3)2, Fe3O4, and Fe3O4-NH2@CS/CuO nanocomposite cell viability was very low against human gastric cancer cell lines i.e. MKN45, AGS, and KATO III and human colorectal carcinoma cell lines i.e. HT-29, HCT 116, HCT-8 [HRT-18], and Ramos.2G6.4C10. The IC50 of Fe3O4-NH2@CS/CuO nanocomposite against MKN45, AGS, KATO III, HT-29, HCT 116, HCT-8 [HRT-18], and Ramos.2G6.4C10 cell lines were 517, 525, 544, 282, 214, 420, and 477 µg/mL, respectively. Thereby, the best anti-gastro-duodenal cancers findings of our Fe3O4-NH2@CS/CuO nanocomposite was seen in the HCT 116 cell line case.

BACKGROUND:Circular RNAs (circRNAs) have been disclosed to exert important roles in human cancers, including gastric cancer (GC). CircRNA hsa_circ_0000144 was identified as an oncogene in GC development. The aim of our study was to explore the role of hsa_circ_0000144 in oxaliplatin (OXA) resistance of GC.METHODS:Expression levels of hsa_circ_0000144, microRNA-502-5p (miR-502-5p) and A disintegrin and metalloproteinase 9 (ADAM9) were examined by quantitative real-time PCR (RT-qPCR) or Western blot assay. The OXA resistance of GC cells was evaluated by Cell Counting Kit-8 (CCK-8) assay. Colony formation assay was performed to assess the colony formation capacity. Cell apoptosis was determined by flow cytometry and caspase 3 activity. And cell migration and invasion were detected by Transwell assay. Target association between miR-502-5p and hsa_circ_0000144 or ADAM9 was demonstrated by dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Moreover, role of hsa_circ_0000144 in vivo was analyzed by xenograft tumor assay.RESULTS:Hsa_circ_0000144 and ADAM9 were highly expressed, while miR-502-5p was downregulated in OXA-resistant GC tissues and cells. Depletion of hsa_circ_0000144 could inhibit OXA resistance, proliferation and metastasis in OXA-resistant GC cells, which was attenuated by miR-502-5p inhibition. Hsa_circ_0000144 sponged miR-502-5p to positively regulate ADAM9 expression. MiR-502-5p suppressed OXA resistance, proliferation and metastasis in OXA-resistant GC cells by targeting ADAM9. Hsa_circ_0000144 knockdown could hamper tumor growth in vivo.CONCLUSION:Hsa_circ_0000144 exerted inhibitory effects on OXA resistance, proliferation and metastasis of OXA-resistant GC cells by regulating miR-502-5p/ADAM9 axis, at least in part.

In the research, two novel coordination polymers based on Cu(II) ion as the metal source and their nanostructures have been prepared via utilizing two ligands of positional isomeric pyridine carboxylic acid 2-(5-carboxypyridin-3-yl)terephthalic acid (H 3 L 2 ) and 4-(6-carboxypyridin-3-yl)phthalic acid (H 3 L 1 ) under the conditions of ultrasonic and solvothermal reaction, and their chemical formulas are {[Cu 3 (L 1 ) 2 (H 2 O) 6 ](H 2 O) 7 } n ( 1 ) along with {[Cu 3 (L 1 ) 2 (H 2 O) 2 ](H 2 O) 2 } n ( 2 ). In addition, the treatment effect of 1 and 2 on the human cancer in vitro and in vivo was detected. The Cell Counting Kit-8 (CCK8) method was used to determine the proliferation of human lung cancer cell line (NCI-H292) after nanoparticles 1 – 2 treatment, the results exhibited that nanoparticle 1 had excellent inhibitory function on NCI-H292 cell viability. Besides, ROS accumulation in the NCI-H292 cells was detected by reactive oxygen species (ROS) assay and annexin V-FITC/PI assay was conducted to detect the apoptotic cells numbers of NCI-H292 cells induced by nanoparticles 1 – 2 treatment. In addition, the tumor model was established in vivo and the treatment ability of the nanoparticle on NCI-H292 tumor was evaluated by measuring the mice weight and tumor volume.

目的 探讨中晚期食管癌患者循环外泌体miR-20a和HER-2蛋白表达与同步放化疗疗效的关系.方法 选择2016年7月至2018年4月期间在皖南医学院第一附属医院接受治疗的67例初诊中晚期食管癌患者,行常规同步放化疗.采用实时荧光定量PCR(QPCR)检测外周血外泌体中miR-20a的表达,采用免疫组化SP法检测活检组织中HER-2蛋白的表达量.分析两者表达与食管癌临床病理特征的关系.绘制受试者工作特征(ROC)曲线评价miR-20a预测疗效的效能.采用双荧光素酶报告基因实验验证miR-20a与HER-2的靶向关系.结果 食管癌患者循环外泌体miR-20a表达水平为1.07±0.40,其中32例患者miR-20a高表达,35例低表达;37例HER-2蛋白阳性,30例阴性.循环外泌体miR-20a表达仅与肿瘤直径、分化程度、临床分期有关(P＜0.05),HER-2表达与临床病理特征均无关(P＞0.05).治疗有效组(n=44)患者循环外泌体miR-20a高表达率和组织HER-2阳性表达率明显低于治疗无效组(n=23)患者,差异有统计学意义(P＜0.05).循环外泌体miR-20a预测中晚期食管癌患者同步放化疗疗效的ROC曲线下面积为0.700(95％CI:0.567～0.833,P=0.007).截断值为1.205.双荧光素酶报告基因实验证实,HER-2与miR-20a存在靶向关系.结论 中晚期食管癌患者循环外泌体miR-20a调控HER-2表达,有望成为预测同步放化疗敏感性的辅助指标.

目的：比较恶性胶质瘤术后单纯放疗与放疗同步替莫唑胺（TMZ）的疗效。方法：选取我院于2007年3月至2014年3月收治的75例患者，随机分为观察组与对照组，其中对照组36例，单纯放疗，总剂量60Gy/30次；观察组39例，放疗期间TMZ 75mg/m2/日，放疗结束后4周，再服用6个周期。结果：对照组和观察组总有效率（C R+P R）分别为44.44%和74.36%，1、2、3年生存率分别为55.56%、27.78%、13.89%和79.49%、51.28%、35.90%，中位复发时间及中位生存时间为14.78个月、20.42个月和20.69个月、26.44个月；以上差异均有统计学意义（P＜0.05），不良反应观察组较对照组稍增加；观察1组和观察2组1、2、3年生存率分别为81.82%、68.18%、45.45%和76.47%、29.41%和23.53%，其中2年生存率有统计学意义（P＜0.05）；两组中位复发时间及中位生存时间为25个月、30.50个月和15.06个月、20.53个月（P＜0.05），不良反应差异无统计学意义（P＞0.05）。结论：放疗同步TMZ治疗恶性胶质瘤的效果明显优于单纯放疗，虽不良反应有所增加，但均可耐受。

选取2012年4月～2014年3月收治的76例子宫颈癌患者进行治疗，随机分组，观察组50例患者采用放疗和顺铂的联合治疗，对照组26例患者仅给予放疗治疗，观察患者的治疗效果。观察组治疗总有效率为98.0%，不良反应发生率为16.0%，对照组治疗总有效率为73.08%，不良反应发生率为42.3%，差异较大，有统计学意义（P＜0.05）。中晚期子宫颈癌患者采用放疗和顺铂的综合治疗，可明显缓解病情，减轻疼痛，提高治疗效果和生活质量，值得推荐。

Objective The clinically investigate whether daily pretreatment with ambroxol(A) could reduce the incidence of acute and chronical radiation-induced pneumonitis in radiotherapy for esophagus cancer.Methods Patients(n=80)with 6MV X-ray radiotherapy(RT) received a daily fraction of 200cGY/5days/week in an approximately total dose of 6400cGY with or without ambroxol 90mg ivd bid,starting on the first day of radiotherapy.Acute and chronical radiation-induced pneumonitis were graded from 0 to 4 according to RTOG.Results The patients' data(n=80) were evaluated.One month post-RT for the incidence of pneunonitis was 26.32% of patients in the RT group and 7.69% in the RT+A group experiencing≥Grade 2 pneumonitis.There was a significant difference between the two groups.At the end of the 6th and 12th months,fibrosis was present in 21.05% and 28.95% receiving RT vs 7.69% and 10.26% receiving RT+A.There was a significant difference between them.Conclusions Ambroxol can reduce the incidence of pneumonitis and fibrosis in radiotherapy for esophagus cancer.

Objective:To evaluate the immediate efficacy and toxic effects of CMNa combing with radiotherapy in treatment of tumors.Methods: 30 cases of tumor patients undergone CMNa with radiotherapy treatment were compared with those 30 cases who only received routine radiotherapy for examining the results.Results: Patients in sensitization group got a complete relief rate of 70%(21 cases) while there was only 43.33% in routine radiotherapy group(13 cases).There showed no difference in toxic effects in both group.Conclusion: Immediate efficacy of CMNa combing with radiotherapy can outweigh simple radiotherapy.